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Abstract
Background: Despite smoking cessation can largely improve cancer prognosis and quality of life, many patients
continued smoking after the diagnosis of cancer. This study aims to test the effectiveness of a smoking cessation
intervention using risk communication approach to help cancer patients quit smoking, and to improve their health
related quality of life.
Methods: A cluster randomized controlled trial will be employed. Cancer patients who continued smoking after the
diagnosis of cancer and have medical follow-up at the out-patient clinics of the five acute hospitals in Hong Kong will
be invited to participate. Subjects in the experimental group will receive (1) health warnings of smoking based on
a special designed leaflet; and (2) a patient-centred counseling from nurse counselors with emphasis on risk
perceptions of smoking to cancer prognosis. Additionally, they will receive two more telephone counseling at
1-week and 1-month. Control group receive standard care and a generic self-help smoking cessation booklet.
Outcomes measure include (a) self-reported and the biochemically validated quit rate, (b) patient’s smoking
reduction by at least 50 % compared to baseline, (c) quit attempt(s), (d) change in the intention to quit, (e)
change in risk perceptions of smoking, and (f) change in health related quality of life.
Discussion: This study will make an important contribution to evidence-based practice by testing the effectiveness of
a tailored smoking cessation intervention for cancer patients. The results will support the development of clinical
practice guidelines to promote smoking cessation in cancer patients to improve their prognosis and quality of life.
Trial registration: ClinicalTrials.gov NCT01685723. Registered 9 November 2012.
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Background
Smoking is the most significant preventable cause of
cancer in the world [1]. Research indicates that current
smokers have a twofold to threefold increased risk of
cancer, and about 90 % of lung cancers are attributed to
smoking [2, 3]. Apart from lung cancer, cigarette smok-
ing can cause many different types of cancer including
cancer of the oropharynx, larynx, oesophagus, trachea,
bronchus, acute myeloid leukaemia, stomach, liver,
pancreas, kidney, ureter, and bladder, and colorectal [2].
Recent advances in medical technology have dramatic-
ally improved the survival rate for most types of cancer.
However, cancer patients who continue to smoke are at
greater risk for second primary, cancer recurrence, and all
causes of mortality [4]. Furthermore, cigarette smoking
can not only reduce the effectiveness of medical treat-
ments for cancer including radio- and chemo-therapies
[5, 6], but also increase the risk of therapy-related side-
effects [7]. Conversely, there is strong evidence that quit-
ting smoking after being diagnosed with cancer could
reduce the risk of disease advancement [8], minimize
adverse treatment-related effects, improve prognosis, and
enhance the quality of life [9]. Given the beneficial effects
of cigarette smoking cessation and the hazardous effects
of continued smoking on cancer patients’ physical and
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psychological health, it is of paramount importance for
healthcare professionals to help this vulnerable group to
quit smoking [10].
Medical attention at out-patient clinics of smokers who
had been diagnosed with cancer can be developed as an
excellent “teachable model” as it provides an invaluable
opportunity for them to initiate smoking cessation to im-
prove their health. It also presented healthcare profes-
sionals with a golden opportunity to advise smokers to
quit while they are waiting for medical consultation or
follow-up. Nevertheless, cigarette smoking is addictive
and quitting is very difficult, with a high rate of relapse,
particularly among those chronic patients with high nico-
tine dependency [11, 12]. Previous studies showed that
47 % smokers with lung cancer in USA and about one
third of cancer patients in western countries continued to
smoke after receiving a cancer diagnosis [4, 13–15].
In a recent qualitative study [16] investigating the risk
perceptions, and the behaviour, attitudes, and experi-
ences of Chinese current smokers and ex-smokers who
have been diagnosed with cancer, the results reveal that
many of the informants had inadequate knowledge of
the association between smoking and cancer. Besides,
many informants who continued smoking were unaware
of the beneficial effects of quitting, including ameliorat-
ing adverse effects of treatment and improving prognosis
and quality of life. Furthermore, many informants had
misconceptions that a moderate amount, such as half a
pack of cigarettes per day, was not detrimental to their
physical health. Some even believed that quitting would
harm their physical well-being as their bodies had be-
come desensitized to the chemicals in tobacco after
long-term smoking. Additionally, some informants were
worried about losing the “psychological benefits” of
smoking once they quit and thus perceived barriers to
quit outweighed the perceived benefits. The findings of
this study [16] address an important yet under-
researched area, as very few smoking cessation programs
targeting cancer patients, and only very few healthcare
professionals help this vulnerable group to quit smoking
[17]. There is an imperative need for healthcare profes-
sionals to design special interventions that use strong
warning to clearly communicate the risk of continued
smoking to this group as a strategy to enhance their
motivation to quit. The findings of the study [16] pro-
vide a guide for developing an effective intervention
protocol that will demystify the misconceptions about
smoking among these vulnerable individuals and in-
crease their perception of the risks of continued smok-
ing and benefits of quitting.
Current study
The present study aims to test the effectiveness of a spe-
cially designed smoking cessation intervention using a
risk communication approach for cancer patients who
are smokers, to (i) achieve a higher quit rate, (ii) im-
prove their smoking behaviour, (iii) motivate their
intention to quit smoking, (iv) improve their risk percep-
tions of continued smoking, and (v) improve the quality
of life.
Conceptual framework
The theoretical framework is shown in Fig. 1. The
framework is constructed with reference to the nicotine
addiction context in smoking [18], and a modified
Theory of Planned Behaviour (TPB) to guide the devel-
opment of the smoking cessation intervention [19]. We
assume smokers who have cancers will quit smoking if
they have positive attitudes, subjective norms and
perceived control on quitting, while the antecedents are
mediated by intention. In addition, we will use a risk
communication approach in the Self-Regulation Model
of Illness [20] to influence patients’ attitudes toward
quitting (behavioural beliefs) and their normative beliefs.
We will apply part of the Transtheoretical Model (TTM)
to guide the risk communication (in form of the pros
and cons of behavioural change) and increase the self-
efficacy of participants [21]. The concept of risk percep-
tions have been found to be a cue to promote healthy
behaviour among patients.
Methods/Design
The study design is shown in Fig. 2. It is a cluster ran-
domized controlled trial to test the effectiveness of a
smoking cessation intervention using risk communica-
tion approach to help cancer patients quit smoking. The
settings will be the oncology out-patient clinics of the
five acute hospitals in Hong Kong.
Study sample and recruitment
Cancer patients fulfilling the following inclusion and ex-
clusion criteria will be invited to participate in the study.
The inclusion criteria are: (1) smoked weekly in the past
6 months, (2) diagnosed with cancer that are related to
smoking [2], such as cancer of the oropharynx, larynx,
lung, oesophagus, trachea, bronchus, acute myeloid
leukaemia, stomach, liver, pancreas, kidney, ureter, and
bladder, and colorectal, (3) diagnosed with cancer for at
least 6 months (such that their conditions and treat-
ments would be stable), (4) patients in all stages I, II, III,
or IV, (5) aged 18 or above, and (6) can communicate in
Cantonese. The exclusion criteria are: (1) those with
unstable medical conditions as advised by the doctor in
charge, (2) poor cognitive state, (3) having mental illness,
and (4) those participating in other smoking cessation
program. The oncologists and oncology nurses will
assess and inform us the stability and suitability of the
cancer patient to participate. The patients would be at
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different phases/ stages but they will also be eligible, if
confirmed by the oncologists/ oncology nurses.
Procedure
Approval for the study has been obtained from five hos-
pital ethics committees (Kowloon West Cluster Research
Committee; Hong Kong East Cluster Ethics Committee;
Kowloon Central/Kowloon East Research Ethics Commit-
tee; Hong Kong West Cluster Ethics Committee; and
New Territories West Cluster Clinical & Research Ethics
Committee). To ensure the rights of all participants will
be protected, the research carried out will be in compli-
ance with the Helsinki Declaration (http://www.wma.net/
en/30publications/10policies/b3/index.html). Research as-
sistants will approach patients in the oncology out-patient
clinic and ask them whether they are smokers or not. The
eligible subjects will then invite to participate in this study
after they are told the purpose of the study. They will be
given the option of participating or refusing involvement
in the study and will be told that their participation is
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Fig. 1 Theoretical framework – a modified Theory of Planned Behavior (TPB) model
560 eligible cancer patients
Experimental group (n=280)
• Health warning on smoking (with a special 
designed leaflet) by oncologist/nurse
• Face-to-face individual smoking cessation 
counseling by nurse counselor (15-30 mins.)
•Assessment of exhaled CO level at baseline
• Generic self-help smoking cessation booklet
•Up to 8 telephone follow-ups within one 
month (10-15 mins.)
Control group (n=280)
• Usual care by oncologist/nurse
• General care and support by nurse counselor 
(5 mins.)
• Generic self-help smoking cessation booklet
• Up to 8 telephone follow-ups to show 
support and care on patients’ disease 
condition (5 mins.)
Cluster randomization (based on OPD session)
3-month telephone follow-up survey
6-month telephone follow-up survey; Biochemical validation if participants quit smoking
9-month telephone follow-up survey
12-month telephone follow-up survey
Sign consent form and complete baseline questionnaire
Fig. 2 Study protocol (CONSORT diagram)
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voluntary without prejudice. Written consent will then
obtain from all participants.
To evaluate the effectiveness of a smoking cessation
intervention using risk communication approach, a total
of 560 eligible Chinese cancer patients were recruited
from five out-patient clinics in Hong Kong. After complet-
ing the baseline questionnaire, subjects will receive pro-
posed intervention according to their group assignment.
Four consecutive (3-, 6-, 9- and 12-month) follow ups will
be conducted by trained interviewers (blinded to the
group assignment) with all subjects via telephone. We will
assess hospital readmission and other clinical outcomes
from the participants’ medical records accordingly. Pa-
tients who have successfully quit smoking at 6-month will
be invited to come back to the out-patient clinic and have
biochemical validation tests (saliva cotinine test and
exhaled CO test). We will offer HKD300 (USD38.5) per
client to cover their travel expenses and time cost. From
our previous experience, such an incentive is necessary to
secure a sufficiently high response rate.
Training and quality assurance of the nurse counsellors and
research assistants
All the research nurses are qualified smoking cessation
counsellors, and they will be provided with specific
training workshop by the principal and co-investigators
prior to the commencement of the study. They will be
equipped with the necessary knowledge and skills to
deliver both the smoking cessation counselling using the
motivational interviewing techniques and stages of
change model. Regular case conference, quality checks
through audio-taping, and audit procedures will be
conducted to ensure and maintain the quality and
uniformity of the counselling interventions. The research
assistants will be trained by the principal and co-
investigators to screen eligible case, conduct baseline
and follow-up surveys and procedures of biochemical
validations (saliva cotinine test and exhale CO test).
Briefing sessions will also be provided to oncologists and
oncology nurses in using the special designed leaflets.
Since the same batch of oncologists and oncology
nurses working in the setting would contact cancer
patients in both the intervention and control group, a
quality assurance mechanism will be used to prevent the
contamination of intervention and control group: (1) a
clear instruction and reminder will be given to the par-
ticipating doctors and nurses before the start of the RCT
study, and we will explain the principle of RCT and
reinforce them the different treatments for the experi-
mental and control groups; (2) a specific risk communi-
cation leaflet will be attached in front of the patients’
medical records in the intervention sessions, and doctors
and nurses will fill up a checklist to make sure if they
have delivered the intervention at the end of each
consultation; (3) patients in the experimental group will
be invited to complete a satisfaction survey during tele-
phone follow-up to see if they have received the risk
communication messages from physicians and nurses
during baseline intervention; and (4) doctors and nurses
will be reminded that they need not deliver the interven-
tion during the “control” clinic sessions and only usual
care will be given.
Quality and data security control
This study will follow the protocol of quality assurance
developed by a previous project [22]. The principal and
co-investigators, project coordinator and nurse counsel-
lors will set up orientation meetings with oncologists,
nurse managers and frontier nurses to explain the proto-
col, the flow of logistics and examine the physical
facilities available in the hospital. The principal and co-
investigators will answer any queries raised by oncolo-
gists and nurses immediately at any time point. The
project coordinator will be present during the first week
to monitor the subject recruitment and data collection
process. All blank and completed instruments will be
sealed in separate opaque envelopes, which will be kept
in a locker with keys provided by hospitals, while the
project coordinator will collect the filled instruments
weekly by hand. All collected instruments will be saved
in a locker with keys in the institution of the principal
investigator. The project coordinator and other research
assistants of this project will be responsible to input the
data into SPSS, with the dataset encrypted in an assigned
personal computer.
Randomisation
Randomization will be done with each session in an out-
patient clinic as a cluster unit. Currently there are 10
sessions per week per study site. Before the study, we
will randomly draw the sessions by computer generated
random sequence (block randomization with each
hospital as a block unit), so that 5 sessions will be
treated as intervention group and another 5 sessions will
be treated as control group per week. Participants who
consent to participate in the study will be assigned to
either intervention or control group depending on the
out-patient clinic session that they are seeking consult-
ation. By using this experimental design, we can ensure
similar proportion of smoking cancer patients will fall
into the intervention and control group in each out-
patient clinic, and each out-patient clinic will have a
similar proportion of cancer patients into the interven-
tion/ control group. We expect the intervention and
control group would have similar socio-demographic
profile, smoking history, and clinical history and we shall
check for any differences, and if any, we shall adjust for
them in the analyses. In using the cluster randomization
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design with a session being a cluster unit, the patients
who are randomized into the experimental and control
groups would have less chance to meet each other in the
out-patient clinic and discuss the contents of the smok-
ing cessation interventions.
Intervention
Control group Subjects in the control group will receive
usual care provided at the site, a generic self-help smok-
ing cessation booklet published by the Hong Kong
Council on Smoking and Health, a brief face-to-face
counselling at baseline plus telephone follow ups by
nurses to show support and care on their disease
condition.
Experimental group Apart from receiving a generic
self-help smoking cessation booklet, subjects in the
experimental group will receive a specifically designed
risk communication leaflet from oncologists/ oncology
nurses during the medical consultation. They will be
warned the risk of continued smoking which can affect
their cancer treatment and prognosis. This brief advice
aims to increase the risk perceptions and normative be-
liefs of participants, hence affect their behavioral beliefs
and subjective norms towards quitting. Furthermore,
subjects will receive a patient-centered motivational
intervention by an experienced nurse counsellor focus-
ing on: (1) risk communication based on self-regulation
model of illness for cancer patients; (2) the stage-
matched smoking cessation intervention (Table 1). The
risk communication component focuses on the relation-
ship of smoking and cancer diagnosis, treatment and
prognosis as a trigger to think about quitting. The com-
ponents are modified from another study to help lung
cancer patients quit smoking, with a self-reported quit
rate of 24 % at 6 months [20]. The stage-matched smok-
ing cessation intervention aims to (1) increase awareness
on the needs to quit smoking; (2) motivate and increase
confidence in ability to quit; (3) set a quit plan and boost
their self-efficacy to resist smoking; and (4) discuss pos-
sible withdrawal symptoms and relapse prevention strat-
egies. The counselling process will take about 15–30
min. In addition, each subject will receive at least one
boost up telephone intervention within one week and
another telephone intervention within one month by
nurse counsellor. The follow up intervention aims to
assess the progress of their action plan and barriers
encountered in the behavioral change process as well as
to engage them in the process, enhance their self-
efficacy, and identify individual barriers and facilitators.
Each telephone counselling will take 10–15 min.
Measures
Structured questionnaire
A structured questionnaire will be developed by adopt-
ing or modifying international and/or locally validated
instruments. The questionnaire gathers information in-
cluding smoking and quitting history, risk perceptions of
smoking [23], illness perception [24], intention to quit
smoking (stage of readiness to quit) [21], antecedent
factors of the TPB model (behavioral beliefs, outcome
evaluations, normative beliefs, motivation to comply)
[25], pros and cons of smoking (decisional balance), self-
efficacy to resist smoking [26], quality of life (SF-12 v2)
[27], other lifestyle risk factors (drinking, physical activ-
ities, and fruit and vegetable intake), demographic infor-
mation such as age, gender, and marital status, and
clinical information including height, body weight, body
mass index, time to diagnose cancer, stage of cancer,
number of tumor sites, blood pressure, and history of
surgery, radiotherapy and chemotherapy. The demo-
graphic and clinical information will be obtained from
the medical records.
Process evaluation
Ten patients from the experimental group will be invited
to participate in an in-depth interview after they have
Table 1 Outline of smoking cessation intervention to be
delivered by nurse counselor
At baseline
Stage-matched Smoking Cessation Counseling
(a) Pre-contemplation: Increase awareness of need to change; decisional
balance; applying 5 “R”s: relevance, risks, rewards, roadblocks, repetition
(b) Contemplation: Motivate and increase confidence in ability to quit
smoking; enhancing confidence in quitting by reinforcing achievement
in previous quit attempt(s)
(c) Preparation: Set a quit plan and boost self-efficacy to resist smoking;
discuss possible withdrawal symptoms and relapse prevention strategies
Risk communication via Self-regulation model of Illness
(a) Identity – recognizing the sign and symptoms of cancer
(b) Help patients understand the cause of cancer (smoking)
(c) Explain to patients the consequence of continue smoking or
smoking cessation
(d) Emphasis the stage or cancer prognosis can be controlled by
stopping smoking
(e) Reinforce patients’ abilities to change the overall timeline or
prognosis of cancer if they can quit smoking substantially
At 1-week and 1-month telephone counseling
(1) Assess health-related lifestyle practices with emphasis on smoking
cessation,
(2) Progress of patient’s action plan,
(3) Assess barriers encountered in the behavior change process,
(4) Boost self-efficacy, and
(5) Reinforce cancer related risk perceptions of continue smoking
Li et al. BMC Cancer  (2015) 15:490 Page 5 of 8
completed the 6-month follow up survey to examine
their experience in quitting and the effect of the inter-
ventions from their perspective. Questions such as their
satisfaction, perceptions on the advantages and disad-
vantages of the intervention, and any other suggestions
for improvement will be explored and discussed
Primary and secondary outcomes
The primary outcome is the self-reported 7-day point
prevalence (PP) quit rate of the smoking cancer patients
during 6-month follow up. The secondary outcomes in-
clude (a) self-reported 7-day PP quit rate at 12-month
follow-up and the biochemically validated quit rate at
6-month follow-up (non-smoking status is confirmed by
a carbon monoxide level in expired air < 9 ppm and
saliva cotinine level < 115 ng/mL in parallel test), (b)
percentage of patients reduced smoking by at least 50 %
at 6- and 12-month follow-up compared to baseline, (c)
percentage of patients with quit attempt(s) at 6- and
12-month follow-up, (d) change in the intention to quit
smoking (stage of readiness to quit) at 6- and 12-month
follow-up compared to baseline, (e) change in risk per-
ceptions of continued smoking at 6- and 12-month
follow-up compared to baseline, and (f ) change in
health-related quality of life at 6- and 12-month com-
pared to baseline.
Power calculation
Sample size is calculated by “Power Analysis and Sample
Size (PASS) v. 13” (http://www.ncss.com/pass.html)
and based on the main outcome variable according to
the main hypothesis, the 7-day point prevalence self-
reported quit rate at 6-month in the experimental group
is higher than the control group. A previous RCT study
[28] conducted in Australia, which applied motivational
intervention to 137 smoking patients with mixed cancer
sites. Based on that study, the self-reported 7-day point
prevalence quit rate at 6-month follow up was 29 % for
the intervention group and 18 % for the control group.
To detect a statistical difference at 5 % significant level
and a power of 0.8, 233 patients will be needed in each
of the 2 groups (based on independent samples Fisher
exact test). With reference to the local RCT on smoking
cessation intervention for cardiac patients [22], we
assume a 15 % attrition rate at the 6-month, and 274
patients will be required in each group to achieve a sig-
nificant outcome. Accounting for the clustered random-
ized sampling design with 20 clusters (sessions) and an
intra-class correlation of 0.002, 280 patients will be
required per group, adding up the total sample size to
560 from the experimental and control groups together.
From the information provided by our clinical partners
on site screening, there are around 2000 new patients
per hospital per year. According to our previous
qualitative study [23] conducted in an out-patient clinic
on Chinese current smokers and ex-smokers, about
13.7 % patients continued smoking after receiving a can-
cer diagnosis (274: 13.7 % of 2,000). However, more than
50 % of these smokers were reluctant to quit (137: 50 %
of 274). In a rough estimation, there will be around 700
eligible subjects in five acute Hospital Authority hospi-
tals each year. We have confidence that we can recruit
adequate subjects (560) according to the power analysis
within an 18-month (78-week) recruitment period.
Analysis
Data analysis was performed using the Statistical Pack-
age for Social Science software, version 20.0 for Win-
dows. When assessing the effectiveness of interventions
between the two groups, we will first compare the base-
line characteristics of the patients using chi-square test
for categorical variables and t-test or Wilcoxon rank-
sum test for continuous variables between the experi-
mental and control groups. The primary analysis will be
an unadjusted intention-to-treat analysis of the differ-
ence in self-reported 7-day point prevalence quit rate of
the smoking cancer patients during 6-month follow up
between the two groups. The analysis will be performed
using Pearson’s chi-square test or with the use of Fisher’s
exact test, if there were five or fewer participants per
cell. Similar approach will be used to estimate the differ-
ences in secondary outcomes (e.g. self-reported 7-day PP
quit rate at 12-month follow-up and the biochemically
validated quit rate at 6-month follow-up, percentage of
patients reduced smoking by at least 50 % at 6- and 12-
month follow-up compared to baseline, and quality of
life at 6 and 12 months) between groups. Crude odds ra-
tios (ORs) for quitting will be estimated using logistic re-
gression model and were compared with ORs that were
adjusted for baseline variables (e.g. sex, age, education,
stage of readiness). Those who are lost to follow-up or
refuse to participate in the validation tests, will be
treated as smokers with no reduction in cigarette con-
sumption compared with (a) baseline, as the main ana-
lysis (by intention to treat), (b) the most recent level and
(c) complete case (per protocol) analysis by excluding
subjects with missing data as a sensitivity analysis.
For the process evaluation, all qualitative data from in-
terviews will be tape-recorded and transcribed verbatim.
Content analysis will be employed and themes identified.
The constant comparative method will be used to search
for common constructs and themes about the imple-
mentation and the effect of the intervention as perceived
by the participating subjects.
Discussion
Smoking is the most significant preventable cause of
death, causing six million deaths annually worldwide [1].
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Although the prevalence of smoking has declined signifi-
cantly over the last 50 years, smoking-attributable dis-
ease and death, in particular cancer have risen greatly
[2]. Evidence shows that smoking cessation can largely
improve cancer prognosis and quality of life among can-
cer patients. However, many cancer patients who contin-
ued smoking after the diagnosis often had inadequate
knowledge of the association between smoking and can-
cer, as well as misconceptions about smoking. This study
aims to test the effectiveness of a smoking cessation
intervention using risk communication approach to help
cancer patients quit smoking, and to improve their
health related quality of life.
To the best of our knowledge, this is the first RCT that
will conduct to help cancer patients quit smoking by in-
creasing their risk perception. The originality and signifi-
cance of the research question will address an important
yet under-researched area, as healthcare professionals
often underestimate the value of helping cancer patients
quit smoking. It is anticipated that the results will motiv-
ate more healthcare professionals to help smokers who
have been diagnosed with cancer quit smoking routinely
in clinical and community settings. Meanwhile, it is cru-
cial that healthcare professionals should be offered rele-
vant training so as to enhance their self-efficacy and
confidence in promoting smoking cessation to cancer
patients.
Implications for clinical practice
This study will make an important contribution to
evidence-based practice by testing the effectiveness of a
tailored smoking cessation intervention targeting cancer
patients.
If it is proven to be effective, the findings of this re-
search have great potential to influence practice not just
in out-patient clinics but also in wider health service and
other public sector settings. Most importantly, the re-
sults primarily serve the purpose to support the develop-
ment of clinical practice guidelines and interventions to
promote smoking cessation in cancer patients to im-
prove their cancer prognosis and in long-term, increase
their survival time and quality of life. For the 280 cancer
patients in the experimental group, we expect to help at
least 81 to quit smoking at 6-month (29 %). For the ses-
sions that are randomized as the experimental group, all
cancer patients (no matter they participate or not into
the study) would receive a specially designed leaflet and
health warning from oncologists/ nurses. In addition, all
the 580 subjects would receive a generic self-help book-
let to help them quit smoking. Among the quitters who
have lung cancer, their risk of cancer recurrence can be
reduced by 20–47 %; the mortality rate (all-cause) can
be reduced by 46–66 %; the risk of second primary
tumor can be reduced by 76 % (among those with
limited stage small cell lung cancer); and the likelihood
of 5-year survival can be doubled, compared to still
smokers [16]. Patients with cancer in other sites will also
have clinical benefits after they quit smoking. Subse-
quently, the quality of life among cancer patients who
stopped smoking can also be improved.
Potential limitations or barriers
There are serval potential limitations or barriers of
implementing the proposed intervention in clinical prac-
tice. First, the proposed intervention is relatively com-
prehensive, which generally takes 30 to 45 min to
implement including the baseline assessment. According
to our previous smoking cessation projects in outpatient
clinics, some patients are too impatient to undergo a
long intervention and some are reluctant to participate
for fear that they might miss or experience delays in
their medical consultation or other medical procedures.
Nevertheless, the intervention will only implement
during the waiting time for medical consultation in the
out-patient clinics and all potential subjects will be rein-
forced by nurse counsellors that they will not miss the
medical consultation or medical procedures through
participating in this study. Second, the intervention that
we proposed for the experimental group is not on a one-
off basis. Each subject will receive at least one boost up
telephone intervention within one week and another
telephone intervention within one month by a nurse
counsellor. Such practice may not be feasible in busy
clinical settings in Hong Kong at this moment. Never-
theless, such approach is necessary and crucial as smok-
ing is addictive and quitting is very difficult, with a high
rate of relapse. Based on our previous smoking cessation
projects on promoting smoking cessation, continuous
reminding and offering support is of paramount import-
ance to achieve the ultimate goal of complete cessation.
Indeed, each telephone counselling will take only 10–15
min. If the telephone follow up effect size is proven and
substantial, this would justify additional resources for
such practice. In the short run, smokers may be referred
to smoking cessation hotline for continuous support and
follow up after receiving the initial intervention by
healthcare professionals. Third, we do not use biochem-
ical indicator as the primary outcome, which is more sci-
entific and objective to ascertain whether a person has
successfully quitted smoking. Nevertheless, using
biochemical validation is costly, difficult to obtain for all
subjects, and may not correspond to the time frame of
the assessment. Furthermore, the response rate for par-
ticipating in biochemical validation is far less than self-
report; this situation is not only in Hong Kong but also
has been reported in elsewhere [29]. In fact, subjects
might refuse to comply with a biochemical validation for
a wide variety of reasons unrelated to smoking status,
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continuing to classify all these subjects as smokers
would represent a distortion of the outcome data, result-
ing in a gross overestimate of smoking rates. After that,
we decide to use self-reported 7-day point prevalence
quit rate as the primary outcome.
Conclusion
This study develops and validates practical smoking ces-
sation interventions using risk communication approach
to help cancer patients quit smoking and improve health
related quality of life. It is anticipated that the findings
can support the development of clinical evidence-based
practice guidelines to promote smoking cessation in can-
cer patients. Most importantly, it will motivate more
healthcare professionals to participate in helping cancer
patients quit smoking.
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